Skip to main content

Advertisement

Table 1 Baseline characteristics at enrollment

From: Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial

  AS-SMP
3 days
(N = 476)
AS-SMP
24 hours
(N = 458)
AL
3 days
(N = 450)
Age (Years)    
   Median 8.0 9.0 8.0
   Min, Max 0.4, 63.5 0.6, 79.0 0.6, 60.0
Age Group (Years)    
   < 5 – n (%) 153 (32.1) 123 (26.9) 137 (30.4)
Gender    
   Male – n (%) 239 (50.3) 226 (49.3) 223 (49.6)
P. falciparum (/μl)    
   Median (IQR) 8400 (3180–24160) 8000 (3200–19520) 7600 (3120–28140)
Gametocyte carriage – n (%) 6 (1.3) 16 (3.5) 8(1.8)
Fever prevalence* – n (%) 332(69.7) 324(70.7) 316(70.2)
  1. N = effective; Std Dev = standard deviation ; IQR = interquartile range
  2. Fever = temperature ≥37.5°C at enrollment